A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Single and Multiple Ascending Dose Administration in Japanese Healthy Volunteers
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Balcinrenone (Primary)
- Indications Cardiovascular disorders; Heart failure
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 09 May 2019 Status changed from active, no longer recruiting to completed.
- 15 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2019 Planned End Date changed from 17 Apr 2019 to 25 Apr 2019.